Durvalumab (Durva) plus carboplatin/paclitaxel (CP) followed by durva±olaparib (Ola) as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial
Proceedings of the Biennial Meeting of Asian Society of Gynecologic Oncology（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要